PE20141599A1 - Derivados de los nucleosidos sustituidos en 4'-azido, 3'-fluoro como inhibidores de la replicacion del rna del vhc - Google Patents

Derivados de los nucleosidos sustituidos en 4'-azido, 3'-fluoro como inhibidores de la replicacion del rna del vhc

Info

Publication number
PE20141599A1
PE20141599A1 PE2014000990A PE2014000990A PE20141599A1 PE 20141599 A1 PE20141599 A1 PE 20141599A1 PE 2014000990 A PE2014000990 A PE 2014000990A PE 2014000990 A PE2014000990 A PE 2014000990A PE 20141599 A1 PE20141599 A1 PE 20141599A1
Authority
PE
Peru
Prior art keywords
ilo
azide
inhibitors
fluorine
derivatives
Prior art date
Application number
PE2014000990A
Other languages
English (en)
Spanish (es)
Inventor
Mark Smith
Francisco Xavier Talamas
Jing Zhang
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20141599A1 publication Critical patent/PE20141599A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PE2014000990A 2011-12-20 2012-12-17 Derivados de los nucleosidos sustituidos en 4'-azido, 3'-fluoro como inhibidores de la replicacion del rna del vhc PE20141599A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161577712P 2011-12-20 2011-12-20

Publications (1)

Publication Number Publication Date
PE20141599A1 true PE20141599A1 (es) 2014-10-30

Family

ID=47469968

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000990A PE20141599A1 (es) 2011-12-20 2012-12-17 Derivados de los nucleosidos sustituidos en 4'-azido, 3'-fluoro como inhibidores de la replicacion del rna del vhc

Country Status (31)

Country Link
US (1) US9708357B2 (2)
EP (1) EP2794628B1 (2)
JP (1) JP6118336B2 (2)
KR (1) KR101687084B1 (2)
CN (2) CN104011060A (2)
AU (1) AU2012357986B2 (2)
BR (1) BR112014015066A2 (2)
CA (1) CA2869317C (2)
CL (1) CL2014001599A1 (2)
CO (1) CO6990719A2 (2)
CR (1) CR20140255A (2)
CY (1) CY1119015T1 (2)
DK (1) DK2794628T3 (2)
EA (1) EA024847B1 (2)
ES (1) ES2626484T3 (2)
HK (1) HK1200835A1 (2)
HU (1) HUE033332T2 (2)
IL (1) IL232843B (2)
IN (1) IN2014CN04530A (2)
LT (1) LT2794628T (2)
MA (1) MA35749B1 (2)
MX (1) MX350810B (2)
PE (1) PE20141599A1 (2)
PH (1) PH12014501283A1 (2)
PL (1) PL2794628T3 (2)
PT (1) PT2794628T (2)
SG (1) SG11201403086YA (2)
SI (1) SI2794628T1 (2)
UA (1) UA110428C2 (2)
WO (1) WO2013092447A1 (2)
ZA (1) ZA201404444B (2)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
HK1200835A1 (en) 2011-12-20 2015-08-14 Riboscience Llc 4'-azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
CA2873315A1 (en) 2012-05-22 2013-11-28 Idenix Pharamaceuticals, Inc. D-amino acid compounds for liver disease
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
SG11201407336PA (en) 2012-05-25 2015-03-30 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
KR102001280B1 (ko) 2012-10-08 2019-07-17 아이데닉스 파마슈티칼스 엘엘씨 Hcv 감염에 대한 2'-클로로 뉴클레오시드 유사체
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
AU2014272055A1 (en) * 2013-05-16 2015-12-24 Riboscience Llc 4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
JP6743135B2 (ja) * 2015-09-02 2020-08-19 アッヴィ・インコーポレイテッド 抗ウィルス性テトラヒドロフラン誘導体
US12297224B2 (en) * 2018-07-02 2025-05-13 Henan Genuine Biotech Co., Ltd. Crystal form, preparation method, and application of 4'-substituted nucleoside

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU498131B2 (en) 1974-02-26 1979-02-15 Ciba-Geigy Ag Production of cephems by cyclization
US4147864A (en) 1975-02-20 1979-04-03 Ciba-Geigy Corporation Process for the manufacture of 7β-amino-3-cephem-3-ol-4 carboxylic acid compounds
US4322347A (en) 1978-04-03 1982-03-30 Bristol-Myers Company 2-Carbamoyloxymethyl-penicillin derivatives
WO1986006380A1 (fr) 1985-04-30 1986-11-06 Takeda Chemical Industries, Ltd. Composes antibacteriens, utilisation et preparation
JPS6422823A (en) * 1987-07-17 1989-01-25 Asahi Glass Co Ltd Antiulcer agent
US5449664A (en) 1988-11-21 1995-09-12 Syntex (U.S.A.) Inc. Antiviral agents
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
CA2252465C (en) 1996-04-23 2007-07-03 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
AP1019A (en) 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
DK0966465T3 (da) 1997-03-14 2003-10-20 Vertex Pharma Inhibitorer af IMPDH-enzymer
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
AU756627B2 (en) 1998-07-27 2003-01-16 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
ID27787A (id) 1998-08-21 2001-04-26 Viro Pharma Inc Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
BR9913406A (pt) 1998-09-04 2002-01-29 Viropharma Inc Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção
KR20010079907A (ko) 1998-09-25 2001-08-22 비로파마 인코포레이티드 바이러스 감염 및 관련 질병의 치료 및 예방 방법
CA2367017C (en) 1999-03-19 2009-05-26 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
US20040034041A1 (en) 2000-05-10 2004-02-19 Dashyant Dhanak Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
CN101624391A (zh) 2001-06-11 2010-01-13 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
US6887877B2 (en) 2001-06-11 2005-05-03 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
ES2289161T3 (es) 2001-11-02 2008-02-01 Glaxo Group Limited Derivados de 4-(heteroaril de 6 miembros)-acil pirrolidina como inhibidores de hcv.
US20050043545A1 (en) 2001-11-02 2005-02-24 Gianpalol Bravi 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
JP2005511572A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としてのアシルジヒドロピロール誘導体
US20070004669A1 (en) 2002-06-21 2007-01-04 Carroll Steven S Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004014312A2 (en) 2002-08-08 2004-02-19 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
WO2004096235A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
KR101164070B1 (ko) 2003-05-09 2012-07-12 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스 ｎｓ5ｂ 폴리머라제 억제제 결합 포켓
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
PL1713822T3 (pl) 2004-01-30 2010-08-31 Medivir Ab Inhibitory proteazy serynowej HCV NS-3
MX2007006961A (es) 2004-12-10 2007-10-04 Univ Emory Analogos nucleosidos de ciclobutilo 2' y 3'-sustituidos para el tratamiento de infeccciones virales y proliferacion celular anormal.
WO2007020193A2 (en) * 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Antiviral phosphoramidates of 4 ' -substituted pronucleotides
WO2007095269A2 (en) 2006-02-14 2007-08-23 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB2442001A (en) 2006-08-11 2008-03-26 Chembiotech Nanoparticle - i-motif nucleic acid bioconjugates
AU2007342367B2 (en) 2007-01-05 2012-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
EP2166016A1 (en) * 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Phosphoramidate Derivatives of Nucleosides
SG172921A1 (en) * 2009-01-09 2011-08-29 Univ Cardiff Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
WO2011039221A2 (en) * 2009-09-29 2011-04-07 Centocor Ortho Biotech Products L.P. Phosphoramidate derivatives of nucleosides
KR101995598B1 (ko) 2010-07-19 2019-07-02 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
BR112013005872A2 (pt) 2010-09-22 2019-09-24 Alios Biopharma Inc compostos, composição farmacêutica e respectivos usos
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
WO2012048013A2 (en) 2010-10-06 2012-04-12 Inhibitex, Inc. Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
HK1200835A1 (en) 2011-12-20 2015-08-14 Riboscience Llc 4'-azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication

Also Published As

Publication number Publication date
PL2794628T3 (pl) 2017-09-29
AU2012357986A1 (en) 2014-06-19
UA110428C2 (uk) 2015-12-25
EA201491180A1 (ru) 2014-11-28
CA2869317C (en) 2016-05-17
CN104011060A (zh) 2014-08-27
CN108409820A (zh) 2018-08-17
CR20140255A (es) 2014-08-20
BR112014015066A2 (pt) 2017-06-13
SI2794628T1 (sl) 2017-07-31
HK1199037A1 (en) 2015-06-19
US9708357B2 (en) 2017-07-18
AU2012357986B2 (en) 2017-02-02
LT2794628T (lt) 2017-07-10
MX350810B (es) 2017-09-20
PT2794628T (pt) 2017-07-05
JP2015500851A (ja) 2015-01-08
US20140369959A1 (en) 2014-12-18
WO2013092447A1 (en) 2013-06-27
IN2014CN04530A (2) 2015-09-11
EA024847B1 (ru) 2016-10-31
JP6118336B2 (ja) 2017-04-19
EP2794628A1 (en) 2014-10-29
NZ625844A (en) 2016-08-26
ZA201404444B (en) 2015-08-26
PH12014501283A1 (en) 2014-09-08
SG11201403086YA (en) 2014-07-30
CL2014001599A1 (es) 2014-11-03
KR101687084B1 (ko) 2016-12-15
EP2794628B1 (en) 2017-03-29
ES2626484T3 (es) 2017-07-25
IL232843B (en) 2018-02-28
MA35749B1 (fr) 2014-12-01
HUE033332T2 (en) 2017-11-28
KR20140108303A (ko) 2014-09-05
IL232843A0 (en) 2014-07-31
CA2869317A1 (en) 2013-06-27
CO6990719A2 (es) 2014-07-10
DK2794628T3 (en) 2017-07-10
HK1200835A1 (en) 2015-08-14
MX2014007028A (es) 2014-09-16
CY1119015T1 (el) 2018-01-10

Similar Documents

Publication Publication Date Title
PE20141599A1 (es) Derivados de los nucleosidos sustituidos en 4'-azido, 3'-fluoro como inhibidores de la replicacion del rna del vhc
PE20141423A1 (es) Derivados nucleosidos con sustitucion 2',4'-difluoro-2'-metilo como inhibidores de la replicacion del arn del vhc
PE20140522A1 (es) Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
PE20140835A1 (es) Compuestos antivirales
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
EA201170915A1 (ru) Фосфорамидатные производные гуанозиновых нуклеозидов для лечения вирусных инфекций
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
PE20181804A1 (es) Derivados de aminotiazol utiles como agentes antiviricos
AR056850A1 (es) MÉTODOS Y KITS PARA DOSIFICAR NUCLEoSIDOS ANTIVIRALES BETA-D-2',3'-DIDEHIDRO-2',3' DIDEOXI-5-FLUOROCITIDINA
CY1111342T1 (el) Αναστολεας νουκλεοσιδιου toy hcv (ιος της ηπατιτιδας c)
PE20110679A1 (es) Derivados de (4-tert-butilfenil)pirrolidin-2,5-difenil como inhibidores del hcv
CL2008000902A1 (es) Ester isopropilo del acido (s)-2-{[(2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidro-2h-pirimidin-1-il)-4-fluoro-3-hidroxi-4-metil-tetrahidro-furan-2-il-metoxi]-fenoxi-fosforilamino}-propionico; proceso de preparacion, composicion farmaceutica y su uso para tratar hepatitis c, virus del west nile, virus de fiebre amarilla, virus del dengue, rinovirus, virus del polio.
CY1118111T1 (el) Υποκατεστημενα αλειφανια, κυκλοφανια, ετεραφανια, ετεροφανια, ετερο-ετεραφανια και μεταλλοκενια που ειναι χρησιμα για τη θεραπευτικη αντιμετωπιση hcv λοιμωξεων
PE20131165A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
PE20140302A1 (es) Inhibidores del virus de la hepatitis c
PE20151274A1 (es) Inhibidores de erk y sus usos
MX350725B (es) Fosforamidatos de nucleosido.
CL2010000520A1 (es) Forma cristalina del propanoato de (s) - isopropil 2 -(((s) - (((2r,3r,4r,5r) - 5- (2,4-dioxo-3,4-dihidropirimidim-1(2h) -il)-4-fluoro-3-hidroxi-4-metitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino); proceso de preparacion; composicion framaceutica; y su uso para el tratamiento de una infeccion causada por el virus de la hepatitis c.
ECSP10010210A (es) Compuestos nucleósidos antivirales
PE20160120A1 (es) Derivados de nucleosido 4'-fluoro-2'-metilo sustituido
EA201171406A1 (ru) Спирооксетановые производные урацилсодержащих нуклеозидов
PE20170203A1 (es) Derivados de nucleosido sustituidos con 4'-difluorometilo como inhibidores de la replicacion de arn de la influeza
CY1112999T1 (el) Αναστολεις ιου ηπατιτιδας c
CO6561788A2 (es) Inhibidores del virus de la hepatitis c

Legal Events

Date Code Title Description
FC Refusal